Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New Idea To Solve The Turing Problem – If Anyone Notices

Executive Summary

The Fair Pricing Coalition previewed its upcoming ‘first hundred days’ proposal for drug pricing reforms – one of many Washington policy documents that was prepared with a very different election result in mind. But one new idea in the report deserves serious attention because it would actually directly address the ‘repricing’ strategy that drove the headlines over the past year.

You may also be interested in...



Drug Affordability Review By National Academies Kicks Off With Lower Profile Than Expected

A National Academies of Sciences, Engineering and Medicine project on drug access and affordability is kicking off with a very different political backdrop for its deliberations than the one that seemed likely when the working group was selected in late October; its work may still end up mattering a great deal, if and when innovator pricing is back on the table for serious policy review.

The Trump Rally: GOP Sweep Is Good News For Biopharma – But Don’t Get Carried Away

Wall Street has made up its mind that the Nov. 8 US elections were great for biopharma companies. But is it really that clear cut?

Pricing, Innovation & Presidential Politics: Today’s Shocking News

Over the last six months, drug pricing has been a headline issue in no small part thanks to the dynamics of Presidential politics. But latest news about former President Jimmy Carter is a reminder that there is another side of the issue.

Topics

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel